Financial reports
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
12 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
4 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Other Events
19 Mar 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Other Events
22 Jan 24
8-K
Material Modifications to Rights of Security Holders
10 Jan 24
8-K
Seelos Therapeutics Announces Closing of Public Offering
1 Dec 23
8-K
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
30 Nov 23
8-K
Material Modifications to Rights of Security Holders
28 Nov 23
8-K
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
24 Nov 23
8-K
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
24 Nov 23
Registration and prospectus
424B3
Prospectus supplement
15 Mar 24
S-8
Registration of securities for employees
6 Mar 24
S-1/A
IPO registration (amended)
6 Mar 24
D
Exempt offering of security
14 Feb 24
S-1
IPO registration
2 Feb 24
424B5
Prospectus supplement for primary offering
30 Jan 24
S-3
Shelf registration
18 Dec 23
424B5
Prospectus supplement for primary offering
30 Nov 23
424B5
Prospectus supplement for primary offering
28 Nov 23
424B3
Prospectus supplement
28 Nov 23
Proxies
DEFA14A
Additional proxy soliciting materials
2 Jan 24
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
20 Dec 23
DEFA14A
Additional proxy soliciting materials
20 Dec 23
DEF 14A
Definitive proxy
15 Dec 23
PRE 14A
Preliminary proxy
4 Dec 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
PRE 14A
Preliminary proxy
31 Mar 23
Other
EFFECT
Notice of effectiveness
18 Mar 24
EFFECT
Notice of effectiveness
28 Dec 23
CORRESP
Correspondence with SEC
21 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
26 Sep 23
UPLOAD
Letter from SEC
20 Sep 23
EFFECT
Notice of effectiveness
28 Dec 21
CORRESP
Correspondence with SEC
22 Dec 21
UPLOAD
Letter from SEC
21 Dec 21
Ownership
4
Michael Joseph Golembiewski
1 Mar 24
SC 13G
Lind Global Fund II LP
6 Feb 24
4
Raj Mehra
17 Jan 24
4
Michael Joseph Golembiewski
17 Jan 24
4
Richard W Pascoe
8 Jan 24
4
MARGARET DALESANDRO
8 Jan 24
4
Brian Lian
8 Jan 24
4
Daniel J. O'Connor
8 Jan 24
4
Michael Joseph Golembiewski
1 Dec 23
4
Raj Mehra
1 Dec 23